6185.HK

CanSino Biologics Inc. [6185.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

6185.HK Stock Summary

Earnings are expected to rise 918.43% next year

6185.HK has less than 1 year of cash runway

Top 10 Correlated ETFs

6185.HK

Top 10 Correlated Stocks

6185.HK

In the News

6185.HK Financial details

Company Rating

Buy

Market Cap

12.34B

Income

-275.76M

Revenue

6.03M

Book val./share

Cash/share

Dividend

Dividend %

Employees

1.95K

Optionable

Shortable

Yes

Earnings

30 Aug 2023

P/E

-5.82

Forward P/E

490

PEG

0.56

P/S

11.49

P/B

0.83

P/C

P/FCF

-4

Quick Ratio

2.02

Current Ratio

2.63

Debt / Equity

0.4

LT Debt / Equity

0.16

EPS (TTM)

-0.34

EPS next Y

0.05

EPS next Q

EPS this Y

-150.52%

EPS next Y

-115.6%

EPS next 5Y

-115.6%

EPS last 5Y

44.07%

Revenue last 5Y

290.74%

Revenue Q/Q

EPS Q/Q

SMA20

1.08%

SMA50

-6.81%

SMA100

-32.96%

Inst Own

Inst Trans

ROA

-8%

ROE

-13%

ROC

-0.16%

Gross Margin

-18%

Oper. Margin

-133%

Profit Margin

-94%

Payout

-20%

Shs Outstand

521.1M

Shs Float

128.55M

Target Price

52W Range

22.2-147.5

52W High

-83.33%

52W Low

+11.36%

RSI

49.89

Rel Volume

0.06

Avg Volume

2.5M

Volume

155.37K

Perf Week

1.66%

Perf Month

-3.54%

Perf Quarter

-40.89%

Perf Half Y

-45.74%

Beta

0.678662

Volatility

0.58%, 0.66%

Prev Close

-2%

Price

24.5

Change

-1.8%

6185.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0.01	0.01	0.08	17.38	4.17
Net income per share	-0.63	-0.75	-1.55	7.74	-3.91
Operating cash flow per share	-0.57	-0.84	-2.03	8.14	-7.64
Free cash flow per share	-1.3	-1.41	-3.21	3.28	-11.99
Cash per share	0.9	3.71	22.15	31.45	24.07
Book value per share	2.3	7.23	26.29	32.31	27.32
Tangible book value per share	2.07	6.95	25.98	33.74	28.28
Share holders equity per share	2.3	7.23	26.29	32.31	27.32
Interest debt per share	0.69	0.82	0.62	5.64	11.1
Market cap	6.59B	10.7B	34.19B	36.39B	14.71B
Enterprise value	6.69B	10.66B	29.89B	32.31B	14.01B
P/E ratio	-47.68	-69.87	-95.38	19.01	-15.24
Price to sales ratio	5.82K	4.68K	1.84K	8.46	14.26
POCF ratio	-53.32	-62.86	-72.85	18.06	-7.79
PFCF ratio	-23.19	-37.26	-46.2	44.85	-4.96
P/B Ratio	13.13	7.27	5.63	4.55	2.18
PTB ratio	13.13	7.27	5.63	4.55	2.18
EV to sales	5.91K	4.67K	1.61K	7.51	13.59
Enterprise value over EBITDA	-48.17	-77.29	-74.17	16.34	-13.61
EV to operating cash flow	-54.07	-62.65	-63.68	16.04	-7.42
EV to free cash flow	-23.51	-37.13	-40.38	39.82	-4.73
Earnings yield	-0.02	-0.01	-0.01	0.05	-0.07
Free cash flow yield	-0.04	-0.03	-0.02	0.02	-0.2
Debt to equity	0.3	0.11	0.02	0.17	0.4
Debt to assets	0.19	0.09	0.02	0.12	0.24
Net debt to EBITDA	-0.67	0.26	10.68	-2.06	0.67
Current ratio	2.07	6.39	13.13	3.23	2.63
Interest coverage	0	0	0	93.62	-33.11
Income quality	0.89	1.09	1.15	1.06	1.59
Dividend Yield	0	0	0	0	0.01
Payout ratio	-0.05	-0.06	0	0	-0.2
Sales general and administrative to revenue	18.2	27.5	4.47	0.05	0.27
Research and developement to revenue	100.39	66.46	23.11	0.2	0.75
Intangibles to total assets	0.06	0.03	0.01	0.02	0.02
Capex to operating cash flow	1.3	0.69	0.58	-0.6	0.57
Capex to revenue	-141.94	-51.22	-14.6	-0.28	-1.04
Capex to depreciation	-13.37	-5.2	-8.51	-13.59	-5.47
Stock based compensation to revenue	13.94	9.42	0.94	0	0.01
Graham number	5.73	11.06	30.3	74.99	49
ROIC	-0.19	-0.12	-0.06	0.2	-0.12
Return on tangible assets	-0.19	-0.09	-0.05	0.16	-0.09
Graham Net	-0.89	2.27	19.58	19.78	8.35
Working capital	114.32M	669.95M	5.01B	6.41B	4.79B
Tangible asset value	451.06M	1.41B	6B	8.35B	6.99B
Net current asset value	-72.55M	480.26M	4.74B	5.96B	3.51B
Invested capital	0.3	0.11	0.02	0.17	0.4
Average receivables	-201.16M	-58.82M	8.95M	0	0
Average payables	4.27M	6.41M	33.37M	451.57M	547.84M
Average inventory	5.06M	12.42M	93.43M	523.07M	776.7M
Days sales outstanding	-43.71K	2.86K	0	0	0
Days payables outstanding	21.36	15.27K	1.6K	237.21	75.87
Days of inventory on hand	27.28	40.44K	4.51K	246.51	203.17
Receivables turnover	-0.01	0.13	0	0	0
Payables turnover	17.09	0.02	0.23	1.54	4.81
Inventory turnover	13.38	0.01	0.08	1.48	1.8
ROE	-0.28	-0.1	-0.06	0.24	-0.14
Capex per share	-0.74	-0.57	-1.17	-4.86	-4.35

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2020-12-31	2021-06-30	2021-12-31	2022-06-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	0	0	0	0	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0	0	0	0	0
Book value per share	0	0	0	0	0
Tangible book value per share	0	0	0	0	0
Share holders equity per share	0	0	0	0	0
Interest debt per share	0	0	0	0	0
Market cap	0	0	0	0	0
Enterprise value	-4.3B	-3.59B	-4.08B	-1.62B	-694.19M
P/E ratio	0	0	0	0	0
Price to sales ratio	0	0	0	0	0
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	0	0	0	0	0
PTB ratio	0	0	0	0	0
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0	0	0	0	0
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0	0	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0.02	0.13	0.17	0.28	0.4
Debt to assets	0.02	0.09	0.12	0.18	0.24
Net debt to EBITDA	0	0	0	0	0
Current ratio	13.13	2.92	3.23	2.99	2.63
Interest coverage	0	0	0	0	0
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.01	0.01	0.02	0.01	0.02
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	0	0	0	0
ROIC	0	0	0	0	0
Return on tangible assets	0	0	0	0	0
Graham Net	0	0	0	0	0
Working capital	5.01B	5.41B	6.41B	5.99B	4.79B
Tangible asset value	6B	6.92B	8.35B	8.14B	6.99B
Net current asset value	4.74B	4.99B	5.96B	5.27B	3.51B
Invested capital	0.02	0.13	0.17	0.28	0.4
Average receivables	0	0	0	0	0
Average payables	35.42M	0	0	0	0
Average inventory	115.74M	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	0	0	0	0
Capex per share	0	0	0	0	0

6185.HK Frequently Asked Questions

What is CanSino Biologics Inc. stock symbol ?

CanSino Biologics Inc. is a CN stock and trading under the symbol 6185.HK

What is CanSino Biologics Inc. stock quote today ?

CanSino Biologics Inc. stock price is $24.5 today.

Is CanSino Biologics Inc. stock public?

Yes, CanSino Biologics Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.5M
Market Capitalization 12.34B
Employee 1.95K
CEO Dr. Xuefeng Yu Ph.D.
Headquarters Tianjin,CN
IPO Date 2019-03-28
Website https://www.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.